Vertex (VRTX) PT Bumped to $88 at BMO Capital Following Results and Triple Combo Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Harry and Meghan surprised by King Charles' letter on their status
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Qualcomm to issue warrant to Amazon for up to 25M shares
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Jefferies Reiterates Buy on Vertex Pharma (VRTX) Following Investor Event
October 28, 2016 7:54 AM EDTJefferies reiterated a Buy rating and $102.00 price target on Vertex Pharma (NASDAQ: VRTX) following an investor event. Jefferies thought VRTX made a good argument for the viability of their next-gen correctors despite some questions raised about their safety profiles. They pointed out that while the teratogenicity with '440... More
Stifel Positive on Vertex (VRTX) as Triple Combo Moves Forward; PT Trimmed to $108
October 26, 2016 9:22 AM EDTStifel analyst Adam Walsh trimmed his price target on Vertex (NASDAQ: VRTX) to $108.00 (from $109.00) but maintained a Buy rating as the triple combo moves forward.
Walsh commented, "At last, Vertex outlined the path forward for its triple combo regimens, removing an overhang on the stock as the competitive landscape heats up with Galapagos/Abbvie (not... More
Vertex Pharma (VRTX) Misses Q3 EPS by 2c; Plans to Commence Two CF-Focused Phase 2s
October 25, 2016 4:04 PM EDTVertex Pharma (NASDAQ: VRTX) reported Q3 EPS of $0.16, $0.02 worse than the analyst estimate of $0.18. Revenue for the quarter came in at $410 million versus the consensus estimate of $418.37 million.
Vertex also announced the planned initiation of two Phase 2 studies to evaluate the next-generation correctors VX-440 and VX-152 in triple combination regimens with tezacaftor (VX-661) and ivacaftor in people with cystic fibrosis (CF). The Phase 2 study of VX-440 is designed to evaluate the safety and efficacy of 4-week dosing of VX-440 in combination with tezacaftor and ivacaftor in approximately 40 people with CF who... More
